Chitosan treatment results in significantly lower plasma LDL-cholesterol concentrations. To 12 test the working mechanism of Chitosan, we measured plasma surrogate markers of cholesterol 13 absorption, synthesis, and degradation to bile acids corrected for cholesterol concentration (R_sterols). 14 One hundred sixteen obese subjects (BMI 31.7, range 28.1 -38.9 kg/m 2 ) were studied under Chitosan 15 treatment (n=61) and placebo treatment (n=55) 
Introduction 31
Reports on Chitosan treatment in obese subjects have shown contradictory results on the reduction of 32 weight and plasma lipids [1] [2] [3] . Results appear to be dependent on many factors such as the Chitosan 33 product composition (percent of deacetylation and content of vitamin C and tartaric acid) and dosage as 34 well as time of duration of treatment, group size, degree of obesity of subjects and accompanying weight 35 reduction program. The intention for treatment with Chitosan is the binding of fat, cholesterol and bile 36 acids in the stomach and intestine followed by increased fecal excretion of fat and cholesterol metabolites. 37
Plasma total cholesterol is not reduced in all human studies [4] [5] [6] , but in Cochran analysis [1] a small 38 significant effect in favor of Chitosan was established (-0.15 mmol/L (95% CI -0.23 to -0.07)). LDL-39 cholesterol is commonly but not always [4, 6] reduced under Chitosan treatment and a small but 40 significant effect in favor of Chitosan was established (-0.16 mmol/L (95% CI -0.23 to -0.10)) in one study 1
[1], which was the opposite in another study [7] . In animal studies large increasing effects of Chitosan on 2 plasma HDL-cholesterol have been demonstrated [2] but the effect in humans appears significantly but 3 marginally [1]: 0.03 mmol/L (95% CI 0.01 to 0.05). However, in many studies no considerable effects were 4
shown [4, [8] [9] [10] [11] [12] [13] . The mechanism of action of Chitosan has not been fully understood to date. Chitosan is a 5 soluble fiber that consists of polyglucosamine produced by deacetylation of Chitin. The amino groups are 6 protonated in acidic environment. These hydrogen cations are able to bind to carboxylic compounds like 7 fatty acids and bile acids. The major site of action is assumed to take place in the stomach where 8 protonation is maximal favored by hydrogenium production from the goblet cells. However, prior to 9 binding of free fatty acids, dietary triglycerides and phospholipids must be hydrolyzed by gastric lipase to 10 free acids. Cholesterol and esterified cholesterol are not available in negatively ionized form. Under 11 normal conditions bile acids are not present in the stomach. 12
A further effect of Chitosan is gel formation in the stomach [14] [15] [16] . Due to the high viscosity of the 13 gastric content gastric emptying is delayed and rapid satiety is established [17] . With gradually increasing 14 pH in the intestine and reduced ionic binding capacity of Chitosan , the gel transforms into a precipitate. 15 It is assumed that the gel and the precipitate trap lipids and bile acids leading to increased fecal loss, 16 however, in humans increased fat excretion was not confirmed in all studies [18] . Increased fecal 17 cholesterol excretion has not been shown at all in humans. Fecal cholesterol excretion was not increased in 18 the study of Maezaki et al [19] . In mice van Bennekum et al [17] did not find increased fecal excretion 19 neither of cholesterol nor of bile acids under Chitosan treatment. In addition, no reduction of fractional 20 cholesterol absorption rate was found. In contrast, they found a decreased food intake under Chitosan 21 treatment. In rats Chitosan did lead to increased fecal excretion of cholesterol and bile acids [16] . 22 However, Fukada et al [20] showed that Chitosan affected bacterial bile acid metabolism in rats but the 23 quantitative bile acid excretion remained unchanged. In humans, the composition of fecal bile acids 24 changed towards increased proportions of primary bile acids, but the total bile acid excretion rate did not 25 change [19] . Thus, the working mechanism of Chitosan is not clear to date, in particular not in humans.
26
Based on the expected increased fecal excretion of cholesterol metabolites and bile acids, it may be 27 hypothesized that the observed reduction of plasma LDL-cholesterol is accompanied by reduced 28 cholesterol absorption and increased cholesterol and bile acid synthesis. 29 Therefore, to investigate the mechanism of action for the hypocholesterolemic effect of Chitosan in 30 humans, we studied the effect of Chitosan treatment on plasma markers of cholesterol absorption 31 (campesterol, sitosterol, cholestanol), cholesterol synthesis (lathosterol, lanosterol, desmosterol), and bile 32 acid synthesis (7α-hydroxycholesterol, 27-hydroxycholesterol) in obese volunteers. 33
Materials and methods 34

Study Design and Population 35
This study was part of a larger clinical trial designed as a 12-week, single center, randomized, 36 placebo-controlled, double-blind, and parallel group study. or drug abuse, subjects with weight reduction >5 kg within the last 5 months and subjects known to be 7 allergic against crustaceans. Women at child bearing age had to show a negative pregnancy test and 8 provide evidence of proper use of contraceptives or other factors excluding pregnancy to occur during the 9 study. Subjects were not allowed to participate in other clinical trials. 10
After stratification according to their gender, patients were assigned to the respective groups using 11 appropriateblock randomization. The chief investigator, investigators, study staff, bioanalytics and 12 patients were all blinded to the treatment allocation in accordance with the double-blind design. 13
Participants in the Chitosan group (n = 61) received eight Chitosan containing tablets 14 (Biopolymer3200, Certmedica International GmbH, Aschaffenburg, Germany), which were taken twice a 15 day as 4 tablets with the main meal. Biopolymer3200 tablets consist of (ß-1,4-Polymer of D-Glucosamine 16
and N-Acetyl-D-Glucosamine containing >80% Chitosan, 5-10% vitamin C, 1-5% tartaric acid and 5-10% 17
water.
18
The participants in placebo group were given eight placebo tablets divided over two meals which 19 contained 122. desmosterol) and bile acid synthesis (7α-hydroxy-cholesterol, 27-hydroxy-cholesterol) were measured 30 with gas chromatography-mass spectrometry-selected ion monitoring [21, 22] . In order to correct these 31 markers for total cholesterol from the same sample we measured total cholesterol by gas chromatography-32 flame ionization detection [23] . These ratios indicated as R_sterols/oxysterols were used as markers of 33 cholesterol absorption, synthesis and catabolism (= bile acid synthesis). 34
Statistics 35
The changes initiated by Chitosan and placebo treatment were tested against baseline using the two-36 tailed Wilcoxon test. The changes under Chitosan treatment and placebo treatment were compared using 37 the two-tailed Mann-Whitney U test. This was done for the total group as well as for the groups of 38 subjects experiencing an increase or decrease. 
Weight and BMI 8
The reduction in weight and BMI (Table 2a and 
Plasma LDL-cholesterol 12
Plasma LDL-cholesterol (Table 4) 
Plasma HDL-cholesterol 7
Plasma HDL-cholesterol did not significantly change under both placebo and Chitosan treatment 8 ( Table 5 ). The observed changes in both treatment groups did not differ from each other. Also the number 9 of subjects experiencing a decrease or increase was similar. 10 11
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Cholesterol absorption markers 4
Due to significant decreases of plasma total cholesterol under both placebo and Chitosan treatment, 5 only the marker concentrations corrected for the cholesterol concentration R_campesterol, R_sitosterol, 6
and R_cholestanol, were considered. The changes of the cholesterol absorption marker sterols (Tables 6a-7 c) during both treatments were not significant from zero except for reduction of R_cholestanol (Table 6c)  8 under placebo treatment. Also changes found under Chitosan treatment were not different from those 9 under placebo treatment. For all three marker compounds in both groups the changes were significantly 10 and negatively associated with baseline values. However, the slopes and intercepts were not different 11 between treatment groups. 12 
Bile acid synthesis markers 5
R_7α-hydroxycholesterol was significantly reduced only under Chitosan treatment (P=0.0196) ( Table  6 8a). The changes induced by both treatments were not significantly different from each other. During 7 placebo treatment R_7α-hydroxycholesterol was reduced in 67.3% of subjects, while during Chitosan 8 treatment in 60.7% of the subjects (NS). No significant changes were seen in R_27-hydroxycholesterol in 9 both groups (Table 8b ). The changes induced by the two treatments were not significantly different from 10 each other. The relationships between changes and baseline values were not different between placebo 11
and Chitosan treatment, neither for R_7α-hydroxycholesterol, nor for R_27-hydroxycholesterol. 12 
Discussion 5
This paper describes changes of plasma sterols in 61 highly overweight and obese subjects after 6
Chitosan treatment. The study is placebo controlled with a placebo group consistingof 55 subjects. The 7 absolute baseline and cholesterol-corrected sterol concentrations in both treatment groups at baseline 8
were not different. To identify whether a parameter was selectively affected by Chitosan treatment, 9 following criteria were investigated. 10 1. The mean change of the parameter value under Chitosan treatment was compared to mean change 11 induced by placebo treatment. 12 2. For both treatments the parameter were compared to respective baseline values. 
Body weight 19
Both weight and BMI decreased highly significantly under both treatments, but the reductions were 20 not more pronounced under Chitosan treatment compared to placebo . The percentage of subjects 21 undergoing a decrease was also similar in both treatment groups. These data confirm human data 22 obtained in previous studies [5, 12, 24] . Interestingly, under Chitosan treatment but not under placebo 23 treatment, the weight change was highly significantly and positively associated with baseline weight 24 values indicating that the highest reduction is obtained at the lowest weight. It may point out that the 25 selection of strongly overweight and obese subjects was not the best choice to show a weight reduction 26 effect of Chitosan treatment. Furthermore, Chitosan treatment may be most efficient as a weight gain 27 prevention therapy in subjects of overweight. The correlation data also suggest that the weight reduction 28 due to placebo and Chitosan treatments are established with different mechanisms. 29 30
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Plasma cholesterol concentrations 1
Plasma total cholesterol decreased significantly under Chitosan treatment only. This decrease was 2 not significantly different from the decrease obtained with placebo treatment, but much more pronounced 3 (P=0.0007) compared to Placebo treatment (P=0.0553). Therefore, a partial Chitosan dependent effect could 4 be assumed. However, the percentage of subjects undergoing a total cholesterol reduction was only 5 slightly higher in the Chitosan treated group. The correlation data did not indicate a trend to assume that 6 different mechanisms explain the concentration reduction under placebo and Chitosan treatments. LDL-7 cholesterol decreased stronger under Chitosan treatment than under placebo treatment (P=0.0252). 8
Compared to the baseline situation, only Chitosan induced a significant decrease (P<0.0003) in this 9
parameter. Also the percentage of subjects undergoing a decrease of LDL-cholesterol was significantly 10 higher in the Chitosan treated subjects (73,8%) than in placebo treated subjects (48.2%). Thus, according to 11 all three criteria a clear Chitosan induced 5.6% reduction of LDL-cholesterol is achieved vs. 0,9% under 12
Placebo treatment. Assuming that the reduction of LDL-cholesterol is due to trapping of dietary 13 cholesterol in the stomach and intestine, it is of interest to relate this number with the 13% LDL-14 cholesterol reduction in vegan subjects who ingest 90% less cholesterol with the diet compared to 15 omnivores [22] . Lacto vegetarians had a 44% lower cholesterol intake but not a lower plasma LDL-16 cholesterol values [25] . From these numbers a trapping efficiency of 60 to 70% of the dietary cholesterol is 17 predicted under Chitosan treatment. 18
Surrogate markers of cholesterol absorption 19
The major plasma markers of cholesterol absorption are cholestanol and plant sterols campesterol 20 and sitosterol. Plant sterols are known to undergo similar changes in absorption as cholesterol. Only the 21 campesterol concentration showed selectively lowered values under Chitosan treatment. However, 22 plasma cholesterol decreased significantly under both treatments. After correcting the plant sterol 23 concentrations for the cholesterol concentrations, no significant differences remained. Also no differences 24
were found between changes due to Chitosan and placebo. In a recent publication were not different. The percentages of subjects undergoing a R_7α-or R_27-hydroxycholesterol reduction 20 or increase were not different under both treatments. The associations between change and baseline value 21 were significant for 7αOH cholesterol and 27OH-cholesterol under both placebo and Chitosan treatment. 22 However, the slopes and intercepts were not different under both treatments. Therefore, our data do not 23 support an independent Chitosan effect on bile acid synthesis. 24
Placebo effects vs Chitosan effects 25
R_cholestanol decreased significantly under placebo treatment. Other sterols (plasma total 26 cholesterol, LDL-cholesterol, R_lathosterol and R_7α-hydroxycholesterol), were significantly reduced 27 under Chitosan treatment only which suggests an independent Chitosan effect. However, the changes 28 during both treatments were not significantly different, except for LDL-cholesterol. Therefore, the 29 reduction of plasma LDL-cholesterol under Chitosan treatment was the only proven independent effect. 30
Body weight and BMI were also significantly reduced during placebo treatment. These reductions can be 31 explained by the fact that the participants have been advised how to improve the quality of their nutrition 32 and energy expenditure. However, they could eat as usual and more importantly the dietary compliance 33 was not monitored. Interestingly, the reductions in weight and BMI did not differ between placebo and 34 Chitosan treated subjects. Significant changes compared to baseline were observed in both groups 35 (P<0.0001). If the nutritional information is the cause of weight reduction, the mechanism of action should 36 be the same for both treatment groups. However, the significant positive association between the change 37 in body weight and baseline value under Chitosan treatment only suggests a selective mechanism of 38 action. A question is whether the placebo tablet composition may have led to effects. The 55 subjects 39 receiving placebo ingested 8 times 122,50 mg or 980 mg microcristalline cellulose and 8 times 372,50 mg or 40 2980 mg calcium hydrogenphosphate per day. Cellulose is a solid non-soluble fiber with a low but 41 potential capacity to bind sterols. Cellulose, non-digestible for humans, is fuel for the colonic microbiota 42 and a product of their fermentation are the short-chain fatty acids influencing health, blood lipid profiles 43 and reducing body weight [28] . Calcium hydrogenphosphate is a proton donor applied in baking powder. 44
The potential effect of a daily dosage of 3 grams cannot be simply predicted. 45
The dose of Chitosan applied in this study was 4 times the dose used in another study with the same 1 Chitosan product but in combination with a high protein formula replacement of a meal once a day [12] . 2
The placebo group also consumed the meal replacement. The same placebo tablet was used as in the 3 present study, but at a four times lower dose. In this study, plasma total cholesterol and LDL-cholesterol 4 significantly decreased in the Chitosan treated group only. In both cases the changes introduced by 5
Chitosan were significantly larger than by placebo. 6
The results of the present study do not give an explanation for the reduced plasma LDL-cholesterol 7 concentration under Chitosan treatment. The hypotheses that Chitosan treatment creates a reduced 8 absorption of dietary cholesterol partly compensated by an increased cholesterol synthesis rate could not 9 be proven applying the surrogate marker technology. The question remains whether the applied 10 experimental protocol and the measurement of surrogate markers for cholesterol absorption and synthesis 11 have been sufficiently appropriate to test the hypotheses. From previous studies it could have been 12
predicted that the reductions of plasma total cholesterol and LDL-cholesterol would be small, in the order 13 of a few percent. The choice of a placebo controlled study implies the difficulty to differentiate adequately 14 between a placebo effect and a selective Chitosan effect. The difficulty becomes larger when the 15 differences are small. There is still discussion on the validity of surrogate markers for cholesterol 16 absorption and synthesis under cholesterol lowering therapies [26, 27] . In particular, the sensitivity of 17 cholesterol synthesis markers may be considered too low to detect small changes. Furthermore, these 18 markers are considered to represent hepatic cholesterol synthesis. A computer-randomized, double-blind, 19
placebo-controlled, 4-period, balanced, crossover study should be initiated combined with appropriate 20 measurement of daily cholesterol intake and fecal excretion of neutral and acidic sterols as well as plant 21 sterols. A continuous stable isotope feeding method to accurately determine the fractional cholesterol 22 absorption and cholesterol balance procedure to measure cholesterol synthesis should be applied. This 23 approach will give maximal information on independent effects of Chitosan, in particular when 24 participants are fed at the metabolic ward with a strictly controlled diet. Using the same approach various 25 dependencies such as the used Chitosan product (composition, dose, % deacetylation, viscosity index), 26 body weight of studied subjects and experimental conditions (caloric restriction, altered diet 27 composition, altered energy expenditure, normo vs hypercholesterolemic state) should be investigated. 28
Based on these answers the optimal formula and the optimal target patient group for treatment can be 29 assigned. 
